<DOC>
	<DOCNO>NCT00482378</DOCNO>
	<brief_summary>RATIONALE : Radioactive drug , samarium Sm 153 lexidronam pentasodium , may carry radiation directly cancer cell harm normal cell . Zoledronic acid pamidronate may help relieve bone pain cause multiple myeloma . Giving samarium Sm 153 lexidronam pentasodium together zoledronic acid pamidronate may effective treatment multiple myeloma . PURPOSE : This phase I/II trial study side effect best dose samarium Sm 153 lexidronam pentasodium give together zoledronic acid pamidronate see well work treat patient relapsed refractory multiple myeloma bone pain .</brief_summary>
	<brief_title>Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid Pamidronate Treating Patients With Relapsed Refractory Multiple Myeloma Bone Pain</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety tolerability samarium Sm 153 lexidronam pentasodium combination zoledronic acid pamidronate disodium patient relapse refractory multiple myeloma bone pain . ( Phase I ) - Determine clinical response patient treat regimen . ( Phase II ) Secondary - Determine effect regimens change patient-reported bone pain level . OUTLINE : This multicenter , open-label , pilot , phase I , dose-escalation study samarium Sm 153 lexidronam pentasodium follow phase II study . - Phase I : Patients receive samarium Sm 153 lexidronam pentasodium IV 1 minute day 1 . Patients also receive zoledronic acid IV 15 minute pamidronate disodium IV 2-4 hour day 1 monthly thereafter absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos samarium Sm 153 lexidronam pentasodium maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive samarium Sm 153 lexidronam pentasodium MTD determine phase I zoledronic acid pamidronate disodium phase I . Bone pain assess periodically . After completion study treatment , patient follow every 3-6 month 3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Samarium ethylenediaminetetramethylenephosphonate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Relapsed refractory disease , meet 1 follow criterion : Recurrent disease stem cell transplantation Recurrent progressive disease despite treatment ≥ 1 standard regimen ( e.g. , alkylating agent plus glucocorticoid and/or combination vincristine , doxorubicin hydrochloride , dexamethasone ) Measurable evaluable disease , define least 1 follow : Monoclonal protein ≥ 1.0 g serum protein electrophoresis Monoclonal protein ≥ 200 mg 24hour urine electrophoresis Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio Monoclonal bone marrow plasmacytosis ≥ 30 % ( evaluable disease ) Patients must already undergo hematopoietic stem cell collection , believe transplant candidate OR eligible hematopoietic stem cell transplant PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 ( ECOG PS 3 allow secondary pain ) ANC ≥ 1,000/mm^3 Platelet count ≥ 75,000/mm^3 Hemoglobin ≥ 8.0 g/dL ( transfusion allow ) Creatinine ≤ 3 mg/dL Calcium &lt; 15 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 week completion study therapy No impending long bone fracture No active malignancy except nonmelanoma skin cancer carcinoma situ cervix breast No uncontrolled infection No comorbidity would interfere patient 's ability participate trial No know hypersensitivity component samarium Sm 153 lexidronam pentasodium bisphosphonates PRIOR CONCURRENT THERAPY : Recovered prior surgery , radiotherapy , antineoplastic therapy More 4 week since prior melphalan myelosuppressive agent More 2 week since prior nonmyelosuppressive agent ( e.g. , thalidomide highdose corticosteroid ) More 30 day since prior concurrent investigational therapy No prior samarium Sm 153 lexidronam pentasodium strontium chloride Sr 89 No concurrent external beam radiotherapy No concurrent highdose corticosteroid Concurrent chronic steroid ( maximum dose 20 mg/day prednisone equivalent ) allow disorder myeloma ( i.e. , adrenal insufficiency rheumatoid arthritis ) Lowdose steroid allow replacement inhalation therapy No concurrent medication , include follow : Cytotoxic chemotherapy Systemic antineoplastic therapy include , limited , immunotherapy , hormonal therapy , monoclonal antibody therapy Prophylactic hematopoietic growth factor Hematopoietic growth factor allow establish cytopenia therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>pain</keyword>
</DOC>